Novartis AG · SIX:NOVN
Novartis — Investor Presentation (2026)
4 slides from Novartis's investor presentation, Nov 19, 2026
Slide 1: Our Immunology pipeline spans rheumatology, dermatology and allergy, anchored by Rhapsido and ianalumab
Our Immunology pipeline spans rheumatology, dermatology and allergy, anchored by Rhapsido and ianalumab Selected projects (MoA/indication) Pre-clinical Phase I Phase II Phase III Registration Next milestone / status Immunology strategy Cosentyx (IL-17A inhibitor; PMR) Approved Q4 2026 EU / US • Driv
Slide 2: Our Cardiovascular-Renal-Metabolic therapeutic area focuses on areas of high unmet need
Our Cardiovascular-Renal-Metabolic therapeutic area focuses on areas of high unmet need, with a strong mid- and late-stage pipeline Selected projects (MoA/indication) Pre-clinical Phase I Phase II Phase III Registration Next milestone / status CRM strategy Leqvio (PCSK9 siRNA; CVRR-LDLC, secondary •
Slide 3: Robust Oncology pipeline across breast, prostate and hematology, with multi-indication potential via RLT
Robust Oncology pipeline across breast, prostate and hematology, with multi-indication potential via RLT Selected projects (MoA/indication) Pre-clinical Phase I Phase II Phase III Registration Next milestone / status Oncology strategy ECI830 (CDK2i; also in other solid tumors)1 Advancing into Ph II
Slide 4: Our Neuroscience pipeline focuses on multiple sclerosis, neuromuscular and neurodegenerative diseases
Our Neuroscience pipeline focuses on multiple sclerosis, neuromuscular and neurodegenerative diseases Selected projects (MoA/indication) Pre-clinical Phase I Phase II Phase III Registration Next milestone / status Neuroscience strategy Ph III studies positive, US submission Remibrutinib (BTK inhibit